Minneapolis, MN /PRNewswire/ - Precision medicine company OneOme is partnering with PWNHealth to increase patient access to the RightMed® comprehensive test without compromising patient safety.
Until now, patients interested in the RightMed test could only get it by talking to their doctor. Through OneOme's new offering, a patient can now request a RightMed test on OneOme's website. Once a request is initiated, PWNHealth's independent clinical team reviews the request and the health information provided by the patient to determine if the test is right for him or her. If approved, a licensed, independent physician orders the test. When test results are ready, the patient schedules a phone or video consult with a PWNHealth licensed genetic counselor trained in pharmacogenetics to discuss their results. Patients are advised to share their test report with their regular healthcare providers so their results can be integrated into their existing medical records as well as current or future treatment plans. Since a person's DNA does not change, patients' providers may use the results for years to come to help inform their prescription decisions.
"By giving patients the option to request a test through an independent provider network, we are empowering them to take control of their health and get valuable information that could impact their treatment plans — which, in some cases — may have a profound effect on their life," said Paul Owen, CEO at OneOme. "Our vision is to make pharmacogenomic testing available for everyone that qualifies — and this patient-initiated option helps achieve that goal without compromising patient safety."
OneOme's RightMed comprehensive test analyzes a person's DNA to predict how they will respond to more than 340+ medications used to treat more than 30 medical conditions, including anxiety, depression, pain, nausea, cancer, and more. The RightMed test results are a valuable resource for patients to share with their providers who, in turn, may use the results to personalize their patient's prescriptions — which may alleviate often and all-too-common trial and error prescribing process and help reduce medication side effects. OneOme performs the pharmacogenomic testing in a CAP/CLIA-certified laboratory headquartered in Minneapolis.
PWNHealth is a virtual care company that enables access to credentialed and licensed health professionals to facilitate diagnostic testing, treatment, and professional guidance that empowers patients to advocate for their own health. Through independent medical oversight of patient-initiated testing, PWNHealth aims to increase patient access to valuable genetic information while ensuring that patients get the right test for them and facilitate their understanding of their results.
Through this new patient-initiated approach, patients will help drive the adoption of pharmacogenomic testing by increasing its use in clinical settings — all the while helping prescribing physicians develop more personalized treatments for them.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.
PWNHealth is a virtual care company that enables access to diagnostic testing, treatment and professional guidance that empowers individuals to improve their health. Using our physicians and genetic counselors, robust technology platform and patient services center, we provide services nationwide to a broad range of health industry customers. PWN was formed with private equity backing through the acquisition of Medivo's Clinical Services Division and Bind Health. For more information, please visit www.pwnhealth.com.
SOURCE: OneOmeCopyright 2018 PR Newswire. All Rights Reserved